Pulse Explorar nav.journalClub Debates Tendencias Investigadores Revistas

Inicio Explorar nav.journalClub Tendencias

⌘+K

GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk | Synapse

October 27, 2017Journal of Translational Medicine297 citationsOpen Access

GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk

MCMargery A. ConnellyGeneral / Preventive / Lipids JOJames D. OtvosPreventive Cardiology ISIrina ShalaurovaLabCorp (United States)

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Collectively, these findings suggest GlycA is a marker that tracks systemic inflammation and subclinical vascular inflammation. However, larger prospective studies and randomized trials are necessary in order to assess the impact of novel therapies on GlycA in patients with chronic inflammatory conditions, which may be concomitant with cardiovascular benefits.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Connelly et al. (2017) studied this question.

synapsesocial.com/papers/69d8439df4e559c61eae325d https://doi.org/10.1186/s12967-017-1321-6

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Assignment of resonances for ‘acute‐phase’ glycoproteins in high resolution proton NMR spectra of human blood plasma1987 · 200 citations
2Biological Variation of Acute Phase Proteins1993 · 107 citations
3Differences in GlycA and lipoprotein particle parameters may help distinguish acute kawasaki disease from other febrile illnesses in children2016 · 28 citations
4GlycA: A Composite Nuclear Magnetic Resonance Biomarker of Systemic Inflammation2015 · 417 citations
5Novel Protein Glycan–Derived Markers of Systemic Inflammation and C-Reactive Protein in Relation to Glycemia, Insulin Resistance, and Insulin Secretion2016 · 65 citations